Policy & Regulation
Ionpath Receives Thermo Fisher Investment to Support Spatial Proteomics Innovation
12 May 2022 - - US-based laboratory instrument maker Thermo Fisher Scientific (NYSE: TMO) has made a strategic investment in US-based spatial proteomics specialist Ionpath, Inc, the company said.

Details of the investment are not being disclosed.

Ionpath's MIBI (Multiplexed Ion Beam Imaging) technology is delivering on the promise of spatial proteomics by providing unprecedented insights for translational medicine researchers.

Through highly multiplexed, quantitative protein imaging with high sensitivity and true subcellular resolution down to 350 nm, MIBI technology delivers actionable insights of single cells in their complex tissue microenvironment with the throughput and reproducibility required for clinical studies.

Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health.

Ionpath's MIBI (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry, enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis.

With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.


Related Headlines